Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

NCT02811354 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: AZD9291

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]
[object Object]